Natural Alternatives International and CarnoSyn® Brands Publish Clinical Research Demonstrating TriBsyn™ Delivering Exceptional Bioavailability, Increased Efficiency and Paresthesia Elimination

Rhea-AI Summary

Natural Alternatives International (NAII) and CarnoSyn® Brands have published positive clinical trial results for TriBsyn™, their new encapsulated low-dose β-alanine complex. The study, published in Food Hydrocolloids for Health, demonstrated that TriBsyn™ achieved 4.5-fold higher plasma β-alanine levels compared to conventional β-alanine supplementation.

The randomized, double-blind study revealed that a 400mg dose of TriBsyn™ outperformed both 400mg and 1200mg doses of conventional beta-alanine. Notably, TriBsyn™ eliminated paresthesia, a common side effect, scoring 0.62 on the Visual Analogue Score compared to 2.02 and 4.01 for conventional doses.

The patent-pending formulation uses proprietary Hydro Oleo technology, enabling absorption through multiple pathways including direct cellular uptake and gastrointestinal routes. The product aims to improve muscle vitality, working capacity, and cognitive performance, targeting active aging populations, GLP-1 users, and those following plant-based diets.

Positive

• Clinical trial proves superior efficacy of new TriBsyn™ product
• 4.5x higher bioavailability vs conventional beta-alanine
• Patent-pending technology eliminates side effects
• Effective at lower doses (400mg vs 1200mg)

Negative

• None.

CARLSBAD, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. (NAI) and CarnoSyn® Brands today announced the publication of positive clinical trial results in the journal Food Hydrocolloids for Health showing that TriBsyn™ supplementation led to significantly greater bioavailability and efficiency of beta-alanine along with the elimination of paresthesia, a common beta-alanine side effect.

Study Highlights:

• TriBsyn™ is an encapsulated low-dose β-alanine complex.
• TriBsyn™ increased plasma β-alanine 4.5-fold compared to conventional β-alanine.
• TriBsyn™ achieved high plasma concentrations without the sensation of paresthesia.
  

TriBsyn™ is a carnosine booster derived from CarnoSyn^® beta-alanine and formulated using proprietary Hydro Oleo technology. This patent-pending formulation provides higher bioavailability and higher potency, enabling efficacious dosages at lower volumes while effectively eliminating paresthesia. The advanced formulation enables absorption through multiple pathways, including direct cellular uptake and traditional gastrointestinal routes, allowing for superior delivery at both the cellular and systemic levels. Adequate availability of beta-alanine is critical for maintaining muscle and promoting cognitive well-being. Efficacious doses of beta-alanine are often associated with harmless but generally uncomfortable symptoms of paresthesia, discouraging adherence to supplementation.

This study aimed to evaluate the bioavailability, pharmacokinetics, and tolerability of a 400 mg Hydro Oleo encapsulated beta-alanine complex (TriBsyn™) specifically designed to reduce paresthesia. A randomized, double-blind, single-dose, three-treatment, three-way crossover oral bioavailability study was conducted in healthy older adults under fasting conditions. The study compared TriBsyn™ with low (400 mg) and high (1200 mg) doses of conventional beta-alanine. TriBsyn™ (400 mg) achieved a nearly 4.5-fold and 1.3-fold increase in circulating beta-alanine plasma concentrations compared to 400 mg and 1200 mg of conventional beta-alanine, respectively.

Using metrics such as the Visual Analogue Score (VAS) and Qualitative Light Symptoms Inventory (QLSI), sensory side effects were assessed. No paresthesia or adverse effects were reported in the TriBsyn™ group, while the conventional beta-alanine groups exhibited increasing paresthesia with dose. TriBsyn™ (400 mg beta-alanine) recorded a VAS score of 0.62 (indicating almost absent symptoms), whereas conventional β-alanine (400 mg) and conventional β-alanine (1200 mg) scored 2.02 and 4.01 respectively. These results highlight the reduced sensory discomfort in the TriBsyn™ group, despite its higher bioavailability.

“The TriBsyn™ clinical trial results clearly showed the elimination of paresthesia and an increased pharmacokinetic efficiency, confirming enhanced delivery and exceptional bioavailability,” said Ken Wolf, President and COO of Natural Alternatives International. “With its advanced Hydro Oleo technology and carnosine-boosting effects, TriBsyn™ provides scientifically proven claims to improve muscle vitality, muscle working capacity, and cognitive performance. It truly sets a new standard in beta-alanine supplementation and helps fill the gap for healthy aging and wellness solutions—especially for the active aging population, GLP-1 users, and those with plant-based diets.”

About CarnoSyn® Brands:
CarnoSyn® Brands features three clinically studied, patented and patent pending ingredients available exclusively from Natural Alternatives International, Inc.: CarnoSyn® instant release beta-alanine powder, SR CarnoSyn® sustained release beta-alanine tablets, and TriBsyn™ powder. In 2019, CarnoSyn® beta-alanine successfully obtained NDI status from the FDA and received Self-Affirmed GRAS (Generally Recognized as Safe) status. SR CarnoSyn®, an advanced delivery form of CarnoSyn®, received GRAS affirmation in 2017. The new “paresthesia-free” TriBsyn™ powder allows NAI to broaden their product offerings within the dietary supplement category, medical food and other fortified food products. To learn more about CarnoSyn® and SR CarnoSyn® in sports nutrition and wellness, visit www.carnosyn.com and www.srcarnosyn.com. For more information about our latest innovation, TriBsyn™, visit www.tribsyn.com.

About NAI:
NAI, headquartered in Carlsbad, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. NAI’s comprehensive partnership approach offers a wide range of innovative nutritional products and services to clients including scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review, and international product registration assistance. For more information about NAI, please visit www.nai-online.com.

FAQ

What are the key clinical trial results for NAII's TriBsyn™ supplement?

TriBsyn™ showed 4.5-fold higher plasma β-alanine levels compared to conventional supplements and eliminated paresthesia side effects, with a VAS score of 0.62 versus 4.01 for conventional doses.

How does NAII's TriBsyn™ technology improve beta-alanine absorption?

TriBsyn™ uses proprietary Hydro Oleo technology for absorption through multiple pathways, including direct cellular uptake and gastrointestinal routes, enabling superior delivery at cellular and systemic levels.

What is the recommended dosage of NAII's TriBsyn™ compared to conventional beta-alanine?

TriBsyn™ is effective at 400mg, achieving higher plasma concentrations than 1200mg of conventional beta-alanine while eliminating side effects.

Who are the target markets for NAII's TriBsyn™ supplement?

TriBsyn™ targets the active aging population, GLP-1 users, and individuals following plant-based diets, focusing on muscle vitality and cognitive performance.